Menu
1-702-720-6310 info@microcapspecualtors.com

Top Biotech Manager Sells Arena Pharmaceuticals On Today’s Big Gain – Forbes


Forbes

Top Biotech Manager Sells Arena Pharmaceuticals On Today’s Big Gain
Forbes
Today, after a successful phase 2 trial on a rare lung disease treatment, Arena Pharmaceuticals (ARNA) jumped almost 45% to just under $28. Todd Hagopian is taking profits, selling more than half of his ARNA position. Ken Kam: Arena is having a great day!
Biotech company’s stock jumps 40% on promising drug to treat rare lung diseaseCNBC
Arena Pharma’s Stock Could Still Double Even After Tuesday’s Epic RunTheStreet.com
Biotech Beat: Arena Pharmaceuticals, Inc. (ARNA) and Exelixis, Inc. (EXEL)Smarter Analyst

all 124 news articles »

Search